Crossmark

Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)

Published Online: 2023-04-17

Published Print: 2023-08

Authors

Kivitz, Alan

DeHaan, Wesley

Azeem, Rehan

Park, Justin

Rhodes, Sheri

Inshaw, Jamie

Leung, Sheldon S.

Nicolaou, Savvas

Johnston, Lloyd

Kishimoto, Takashi K.

Traber, Peter G. https://orcid.org/0000-0002-5952-5720
Sands, Earl

Choi, Hyon
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02959918 at ClinicalTrials.gov

Documents that mention this clinical trial

Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)
https://doi.org/10.1007/s40744-023-00546-0
License Information

Text and Data Mining valid from 2023-04-17

Version of Record valid from 2023-04-17
More Information

Article History

Received: 11 January 2023

Accepted: 3 March 2023

First Online: 17 April 2023

Document is current